NCT05957367 2026-03-06
A Study of Inlexisertib (DCC-3116) in Combination With Anticancer Therapies in Participants With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1/2 Recruiting
Clinical Trials
80 trialsNCT06760819 2026-03-04
panSOHO
Bayer
Phase 2 Recruiting
NCT07406633 2026-02-12
KQB198 in Combination With Imatinib in Participants With Advanced/Metastatic GIST in 1st Line Setting
Kumquat Biosciences Inc.
Phase 2 Not yet recruiting
NCT03673501 2026-02-05
INTRIGUE
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT06655246 2026-02-05
A Study of Ziftomenib in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Kura Oncology, Inc.
Phase 1 Recruiting
NCT01742299 2026-02-02
Study to Allow Access to Imatinib for Patients Who Are on Imatinib Treatment in a Novartis-sponsored Study and Are Benefiting From the Treatment as Judged by the Investigator
Novartis
Phase 4 Active not recruiting
NCT07218926 2026-01-30
A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy
GlaxoSmithKline
Phase 3 Recruiting
NCT07379047 2026-01-30
GISTAR-1
Ningbo Newbay Technology Development Co., Ltd
Phase 2/3 Not yet recruiting
NCT05734105 2025-12-17
INSIGHT
Deciphera Pharmaceuticals, LLC
Phase 3 Active not recruiting
NCT05489237 2025-11-17
First-in-human Study of IDRX-42 in Participants With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors
IDRx Inc. - A GSK Company
Phase 1 Recruiting
NCT04000529 2025-09-30
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies
Novartis
Phase 1 Terminated
NCT06805825 2025-09-23
A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Express c-Kit
Novelty Nobility, Inc.
Phase 1 Recruiting
NCT03594422 2025-02-27
A Study of HQP1351 in Patients With GIST or Other Solid Tumors
Ascentage Pharma Group Inc.
Phase 1 Recruiting
NCT02401815 2025-02-14
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Cogent Biosciences, Inc.
Phase 1/2 Completed
NCT04633122 2025-02-10
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT04908176 2024-12-13
A Drug-drug Interaction Study of Avapritinib and Midazolam
Blueprint Medicines Corporation
Phase 1 Completed
NCT04825574 2024-11-26
Study for Patients Previously Treated in Avapritinib Clinical Trials
Blueprint Medicines Corporation
Phase 4 Completed
NCT04530981 2024-09-19
A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients with Advanced GIST
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT01863745 2024-08-19
Nilotinib Roll-over Protocol for Patients in Novartis-sponsored Nilotinib Study and Benefiting From Nilotinib Treatment
Novartis
Phase 2 Completed
NCT01294202 2024-08-02
A Study to Investigate the Safety and Efficacy of AT13387, Alone or in Combination With Imatinib, in Patients With GIST
Astex Pharmaceuticals, Inc.
Phase 2 Completed
NCT05160168 2024-06-05
A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)
Theseus Pharmaceuticals
Phase 1/2 Terminated
NCT04714983 2024-04-09
DNX-2440 for Resectable Colorectal Liver Metastasis
DNAtrix, Inc.
Phase 1 Suspended
NCT04276415 2024-02-15
DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)
Daiichi Sankyo
Phase 1 Terminated
NCT04409223 2024-02-09
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of Imatinib
Jiangsu HengRui Medicine Co., Ltd.
Phase 3 Terminated
NCT01735955 2024-02-08
Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Completed
NCT02571036 2023-12-13
A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies
Deciphera Pharmaceuticals, LLC
Phase 1 Completed
NCT02232620 2023-11-14
A Study of BBI503 in Adult Patients With Advanced Gastrointestinal Stromal Tumors
Sumitomo Pharma America, Inc.
Phase 2 Terminated
NCT02034110 2023-08-21
Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers
Novartis
Phase 2 Completed
NCT04254939 2023-04-27
A Study of CS3007 in Subjects With Gastrointestinal Stromal Tumor
CStone Pharmaceuticals
Phase 1/2 Completed
NCT05800106 2023-04-10
A Bioequivalence Study of Sunitinib Malate Capsules.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT00812240 2023-02-01
Masitinib in First Line Treatment of Gastro-Intestinal Stromal Tumor (GIST)
AB Science
Phase 3 Terminated
NCT03353753 2022-11-21
INVICTUS
Deciphera Pharmaceuticals, LLC
Phase 3 Completed
NCT02508532 2022-06-21
(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors
Blueprint Medicines Corporation
Phase 1 Completed
NCT05080621 2022-01-05
Ripretinib in Combination With Binimetinib in Patients With Gastrointestinal Stromal Tumor (GIST)
Deciphera Pharmaceuticals, LLC
Phase 1/2 Withdrawn
NCT01275222 2021-06-25
Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors
Novartis
Phase 1/2 Completed
NCT01271712 2021-01-29
GRID
Bayer
Phase 3 Completed
NCT00135005 2020-12-08
Study of AMN107 With Imatinib in Gastrointestinal Stromal Tumors (GIST)
Novartis
Phase 1 Completed
NCT01694277 2020-12-08
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
AB Science
Phase 3 Completed
NCT02452424 2020-03-05
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Daiichi Sankyo
Phase 1/2 Terminated
NCT02574663 2019-10-02
TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors
TG Therapeutics, Inc.
Phase 1 Completed
NCT04106024 2019-09-26
Efficacy and Safety of Anlotinib in Patients With Advanced Gastrointestinal Stromal Tumor After Failure of Imatinib: a Prospective, Single Arm and Multicenter Trial
Cttq
Phase 2 Unknown
NCT02686944 2019-07-05
GIST
Mendus
Phase 1 Completed
NCT00428220 2019-06-27
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Pfizer
Phase NA Completed
NCT01396148 2019-03-27
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
Pfizer
Phase 2 Completed
NCT01243346 2018-06-28
Study of Crenolanib for the Treatment of Patients With Advanced GIST With the D842-related Mutations and Deletions in the PDGFRA Gene
Arog Pharmaceuticals, Inc.
Phase 2 Completed
NCT01874665 2018-05-18
GIST
Takeda
Phase 2 Completed
NCT02336724 2018-04-17
A Study of Famitinib in Patients With Gastrointestinal Stromal Tumor
Jiangsu HengRui Medicine Co., Ltd.
Phase 2 Unknown
NCT00867113 2018-03-14
Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Novartis
Phase 2 Completed
NCT00455559 2018-02-22
Ph II Study of Perifosine Plus Gleevec for Patients With GIST
AEterna Zentaris
Phase 2 Completed
NCT00633295 2017-06-22
Phase II Study Aiming to Evaluate the Efficacy and Safety of Nilotinib Patients With Gastrointestinal Stromal Tumors (GIST) Resistant or Intolerant to Imatinib and or to 2nd Line Tyrosine Kinas (TK) Inhibitor
Novartis
Phase 2 Completed